News
About Insight Lifetech
我们是一家医疗科技企业,致力于开发可能为心血管疾病诊疗带来变革的精准解决方案。作为心血管介入器械市场的领先企业,根据弗若斯特沙利文的资料,我们开发了中国首个及唯一一个获国家药监局批准的国产血流储备分数(FFR)测量系统。此外,我们的第一代IVUS成像系统为中国首个进入临床试验并完成患者入组的国产IVUS成像系统。根据弗若斯特沙利文的资料,由于我们同时拥有FFR及IVUS产品,我们是中国唯一一家拥有精准血管内生理学及影像学产品组合的国产医疗器械公司。自成立以来,我们一直专注于开发创新技术,以实现心血管疾病的精准治疗,我们的愿景是成为有长久影响力的世界级医疗科技企业。 在强大的管理团队的带领下,我们利用专有技术、深厚的行业洞察力及丰富的研发经验,已开发出一个心血管疾病精准诊疗的整体解决方案平台。我们的产品管线目前包括16个介入式心血管产品及具有全球专利的在研产品,包括我们的FFR测量系统、IVUS成像系统、微导管产品组合、衝击波球囊治疗系统(IVL)及电生理(EP)解决方案,用于诊疗冠状动脉疾病(CAD)、外周动脉疾病(PAD)及房颤。
More
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.